

- Abe E, Yamamoto M, Taguchi Y, et al (2000):** Essential requirement of BMPs 2/4 for both osteoblast and osteoclast formation in bone marrow cultures from adult mice: antagonism by noggin, *J Bone Miner Res*; 15: 663-673.
- Adler RA, Funkhouser HL and Holt CM (2001):** Utility of heel ultrasound bone density in men, *J Clin. Densitom.*; 4: 225-230.
- Amanda D. ,Cathleen S. , Bastian L. ,Matthew ,Kenneth W.(2004):**Does This Woman Have Osteoporosis?, *JAMA*, 292(23): 2890-2900
- An YH, Burgoyne C, Crum M and Glaser A (2002):** Current methods and trends in fixation of osteoporotic bone ,In An YH(eds.) *Internal fixation in osteoporotic bone*, Library of congress Cataloging, United States: p79
- An YH, Young FA, Fang Q, Williams KR (2000):** Effects of cancellous bone structure on screw pullout strength, *Univ South Carolina Orthop J* ; 3: 22—26
- Arokoski MH, Arokoski JP, Vainio P, et al. (2002):** Comparison of DXA and MRI methods for interpreting femoral neck bone mineral density, *J Clin Densitom*; 5(3): 289-96.
- Atik OS , Gunal I and Korkusuz F (2006):**Burden of Osteoporosis , clinical orthopaedics and related research ;443:19–24
- Augat P (2001):** Biomechanical evaluation of a new bioresorbable polymer for screw augmentation in the osteosynthesis of osteoporotic cancellus bone. 47th Annual Meeting, Orthopaedic Research Society, San Francisco, California :p 254.
- Bardet S, Rohmer V, Boux de Casson F, et al. (2002):** Bone mineral density and biological markers of bone repair in patients with adrenal incidentaloma: Effect of subclinical hypercortisolism, *Rev Med Interne*; 23: 508-517.
- Baroncelli GI (2008):** Quantitative ultrasound methods to assess bone mineral status in children: technical characteristics, performance, and clinical application, *Pediatr Res.*; 63 (3): 220-8.
- Bauer DC, Black DM, Garnero P, et al. (2004):** Changes in bone turnover and

- hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial., *Journal of Bone Mineral Research*; 19: 1250–1050.
- Bhagavan NV (2002):** Mineral metabolism, 4<sup>th</sup> ed., Medical Bio chemistry, N.V. Bhagavan (ed.), Academic Press, P. 875.
- Binkley N, Novotny R, Krueger D, et al (2007):** Low vitamin D status despite abundant sun exposure, *J Clin Endocrinol Metab*;92:2130-2135
- Black DM, Delmas PD, Eastell R, et al(2007) :** Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis for the HORIZON Pivotal Fracture Trial , *n engl j med*, 356(18):1809- 1822
- Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, et al (2001):** An assessment tool for predicting fracture risk in postmenopausal women., *Osteoporos Int*, 12:519-28.
- Black DM, Thompson DE, Bauer DC, et al (2000):** Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. Fracture Intervention Trial Research Group., *J Clin Endocrinol Metab*;85:4118-4124.
- Boldin C (2003):** The proximal femoral nail (PFN)-a minimal invasive treatment of unstable proximal femoral fractures. “A prospective study of 55 patients with a follow-up of 15 months”, *Acta. Orthop. Scand.* ;74 (1): 53–58
- Bölgen Ç, Güler H, Günsah S , Özisik S, Bağıs S, Bdçer A, Erdoğan C (2002):** Measurement of Arm Span-Height Difference in Postmenopausal Osteoporotic Women, *T Klin J PM & R*; 2:104-107
- Bone HG, Hosking D, Devogelaer JP, et al (2004):** for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years experience with alendronate for osteoporosis in postmenopausal women., *N Engl J Med*;350:1189-1199.
- Bonnick S, Harris S, Kendler D, McClung M and Silverman S (2010):**Management of osteoporosis in postmenopausal women :2010 position statement of The North American Menopause Society, *The Journal of The*

North American Menopause Society; 17 (1): 25-54

**Borah B, Gross GJ, Dufresne TE, et al. (2001):** Three-dimensional micro-imaging( MR micro I and micro CT) finite element modelling and rapid prototyping provide insights into bone architecture in osteoporosis., *Anat Rec*; 265: 101–10

**Boskey A and Posner A (1994):** Bone structure , composition and mineralization., *Orthop. Clin. North. Am.*; 15: 597-612.

**Bouillon R (2006):** In *Vitamin D: From Photosynthesis, Metabolism, and Action to Clinical Applications*. Degroot, L.J. & J.L. Jameson (eds): Endocrinology, 5th ed. Philadelphia, Elsevier :p 1435.

**Bramlet DG (2004):** Use of the talon hip compression screw in intertrochanteric fractures of the hip., *Clin Orthop* ; 425:93—100

**Brown JP and Josse R. (2002):** 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, *Canadian Medical Association journal* ;167 (10): s1-s34

**Byyny RL and Speroff L (1996):** *A Clinical Guide for the Care of Older Women: Primary and Preventive Care*, ed 2. Baltimore, Lippincott, Williams and Wilkins,1996, p 907

**Camacho P and Kleerekoper M (2006):** Biochemical markers of bone turnover. In Favus M, ed. *Primer on the metabolic bone diseases and disorders of mineral metabolism*, 6th ed. Washington, DC: American Society for Bone and Mineral Research, pp. 389.

**Camacho P, Girgis M, Sapountzi P, et al. (2005):** Correlations between vitamin D, parathyroid hormone, urinary calcium excretion, markers of bone turnover and bone density of patients referred to an osteoporosis center., *J Bone Miner Res*; 20 (1): S389-S450.

**Camacho PM and Miller PD (2007):** Biochemical evaluation. In Camacho PM and Miller PD (eds), *Osteoporosis: A Guide for Clinicians*, 1st Edition.

Lippincott Williams & Wilkins; 68: 63-80.

**Canadian Consensus Conference on Osteoporosis (CCCO) (2006):** Update., J obstet Gynaecol Can; 28 (1):S95–S112.

**Canalis E (1996):** Mechanisms of glucocorticoid action in bone : Implication to glucocorticoid – induced osteoporosis., J. Clinical Endocrine Metabolism; 81 : 3441 – 3447.

**Carmona R, Beato C, Lawrence A, Moritsugu K, Noonan A et al., (2004):** Bone health and osteoporosis: A report of the surgeon general. Found at : [http://www.surgeongeneral.gov/library/bonehealth/docs/full\\_report.pdf](http://www.surgeongeneral.gov/library/bonehealth/docs/full_report.pdf) , accessed: 28 December 2010

**Chesnut CH , Skag A, Christiansen C, et al (2004):** Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res;19:1241-1249.

**Coetzee M and Kruger MC (2004):** Osteoprotegerin-Receptor Activator of Nuclear Factor-[kappa]B: Mechanism of Action between Osteoblasts and Osteoclasts , South Med J. ;97 (5):506-511

**Cohen N, Herling G and Otremski I (2000):** “Under-the-plate” reduction band technique Acta Orthop Scand ;71 (2): 201–203

**Compston J, Cooper A, Cooper C, Francis R, Kanis J, Marsh D, McCloskey E, Reid D, Selby P and Wilkins M (2009):** Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK, Maturitas ;2 :105-206

**Cornell C (2003):**Internal Fracture Fixation in Patients With Osteoporosis , J Am Acad Orthop Surg ;11:109-119

**Cornell C (2005) :** Fixation considerations in osteoporotic bone fractures, Current Opinion in Orthopaedics ; 16:376—381

**Cornish J, Callon KE, Cooper G S and Reid R (1995):** Amylin stimulates osteoblasts proliferation and increases mineralized bone volume in adult mice.

- Biochem. Biophys., Res. Commun.; 207 : 133-139.
- Cosman F (2008):** Parathyroid hormone treatment for osteoporosis, *Current Opinion in Endocrinology, Diabetes & Obesity*; 15:495–501
- Cranney A, Tugwell P, Zytaruk N, et al. (2002):** Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. *Endocrine Review*; 4: 524–528.
- Cummings S (2002):** Bone Biology, Epidemiology, and General Principles. In: Cummings S, Cosman F and Jamal S (eds.) *Osteoporosis: an evidence-based guide to prevention and management*, Philadelphia, American college of physicians : 3-25
- Cummings SR, Bates D, Black DM (2002):** Clinical use of bone densitometry, *JAMA*; 288: 1889-1897.
- Cummings SR, Eastell R, Ensrud K, et al. (2008):** The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial., *J Bone Miner Res*;23(1):S81.
- Cundy T and Reid I (1995):** Metabolic bone disease . In : *Clinical Biochemistry: Metabolic and Clinical Aspects*, W. J. Marshall and S. K. Bangert (eds.), Churchill Livingstone: P. 507.
- Davey DA (1995):** The menopause and climacteric. In: *Dewhurt's Textbook of Obstetrics and Gynecology for postgraduates*, 5th ed., CR. Whitfield (ed.), Blackwell Science :p.609.
- Deal C (2009):** Future therapeutic targets in osteoporosis, *Current Opinion in Rheumatology*;21:380–385
- Delany MF (2006):** Strategies for the prevention and treatment of osteoporosis during early postmenopause., *AJOG*; 194 (2): S12–S23.
- Dell R , Greene D, Schelkun SR and Williams K (2008) :** Osteoporosis Disease Management: The Role of the Orthopaedic Surgeon , *J Bone Joint Surg Am*.

;90 (4) :188-94

**Dennison E, Cole Z and Cooper C (2005):** Diagnosis and epidemiology of osteoporosis, *Curr Opin Rheumatol* ;17:456—461.

**Doursunian L(2000):** A new internal fixation technique for fractures of the proximal humerus--the Bilboquet device: a report on 26 cases., *J. Shoulder Elbow Surg.*; 9:279-88.

**Drazen JM (2008):** Diseases of bone and mineral metabolism. In Goldman L, Ausiello, Arend (eds), *Cecil medicine* (10<sup>th</sup> ed.), Elsevier; 595: 590–601.

**Ebeling PR (2008):** "Clinical practice. Osteoporosis in men"., *N Engl J Med*; 358 (14): 1474-82.

**Fankhauser , Bolden C, Schippinger G, et al (2005):** A new locking plate for proximal humerus fractures. *Clin Orthop* ; 430:176—181.

**FDA (2002) :**Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement; Guidance for Industry and FDA , available at: <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm072837.pdf> , accessed :20 October 2010

**Findlay DM and Sexton PM (2004):** Calcium and phosphorus metabolism, *Growth Factors*; 22: 217–17

**Fishman M. (2009):** Yoga for Osteoporosis: A Pilot Study, *Topics in Geriatric Rehabilitation*;25 (3) :244–250

**Fogelman I and Blake M (2005) :** Strontium ranelate for the treatment of steoporosis, *rBMJ*; 330 :1400-1

**Follin SL and Hansen LB (2003):** Current approaches to the prevention and treatment of postmenopausal osteoporosis., *American Journal of Health-System Pharmacy*; 60 (9): 883–901.

**Fountia website (2010):** history of osteoporosis, available at: <http://www.fountia.com/history-osteoporosis>, accessed: 14 October 2010

- Franck W, Olivieri M, Jannasch O and Hennig F (2002):** An expandable nailing system for the management of pathological humerus fractures. Arch Orthop.Trauma Surg. ; 122:400–405
- Francois MP, Reid MD and Rosner W (2003):** Bone densitometry testing in non-white patients., JAMA; 289 (8): 982–992.
- FRAX WHO fracture risk assessment tool (2010):** Welcome to FRAX®, available at : <http://www.shef.ac.uk/FRAX/> , accessed: 17 October 2010
- Freitag A and Barzel US (2002):** Differential diagnosis of osteoporosis, Gerontology ;48 (2): 98-102
- Friedman PA (2006):** Agents affecting mineral ion homeostasis and bone turnover. In L. L. Brunton, J. S. Lazo, & K. L. Parker (Eds.), The pharmacological basis of therapeutics (11th ed). New York: McGraw-Hill Medical Publishing Division: pp. 1647–1678
- Gallagher C (2007):** Effect of early menopause on bone mineral density and fractures., The Journal of the North American Menopause Society;14: 567-571
- Gangopadhyay S, RILEY N and SIVAJI C (2010):** Expanding nail or expanding femur? An adverse event with the expandable intramedullary nail , Acta Orthop Traumatol Turc ;44(2):166-168
- Girasole G, Jilka RL, Passeri G and Boswell S (1992):** 17-  $\beta$ - estradiol inhibits interleukin-6 production by bone marrowderived stromal cells and osteoblasts in vitro : a potential mechanism for the antiosteoporotic effect of estrogen., J. Clin. Inv.;89 : 833-897.
- Gold DT, Lyles KW, Shipp KM, Drezner MK (2001):** Osteoporosis and Its Non-Skeletal Consequences: Their Impact on Treatment Decision. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. Ed 2:479-484.
- Grabo TN and Longyhore DS (2008):** Pharmacological management. In Gueldner SH, Grabo TN, Newman ED (eds), Osteoporosis: Clinical guidelines for prevention, diagnosis and management(5<sup>th</sup> ed.), Springer Publishing

Company :47–82

**Gulli L (2002):** Hormone replacement therapy. In Jacqueline L. Longe (Ed.), Gale Encyclopedia of Medicine Vol. 3, (2nd ed.): pp. 1668–1673.

**Haddad FS et al (2002):** Periprosthetic femoral fractures around well-fixed implants: use of cortical onlay allografts with or without a plate., J Bone Joint Surg Am. ;84: 945-50.

**Halpin R, Bendok B and Liu J(2004):** Minimally Invasive Treatments for Spinal Metastases: Vertebroplasty, Kyphoplasty, and Radiofrequency Ablation ,the journal of supportive oncology ;2 (4) : 339-355

**Halsey MF, Mcleod k and Rubin C (1997):** The biology of bone . In : Principles of Orthopaedic Practice. 2<sup>nd</sup> ed. R. Dee, L.C. Hurst, M.A. Gruber and S.A. Kottmeier (eds.) , Library of congress., PP. 22-25.

**Hargrove JT and Eisenberg E (1995):** Menopause, Med Clin North Am., 79: 1337-1356.

**Haussler B, Grothe H, Gol D, et al. (2007):** Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study., Osteoporosis Int; 18: 77–84.

**Hinman R (2004) :** Comparison of thoracic kyphosis and postural stiffness in younger and older women, The Spine Journal ;4:413–417

**Hipprotector website (2010):** How do Hip Protectors Work? , found at: <http://www.hiprotector.com/works.html>, accessed: 10 January 2011

**Hodgson SF, Watts NB, Bilezikian JP, et al. (2003):**AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001edition, with selected updates for 2003. Endocrine Practice; 9 (6): 544–564.

**Hofer AM and Brown EM (2003):** Calcium and phosphorus metabolism., Nat. Rev. Mol. Cell. Biol; 4: 530–550.



- Holick MF (2004):** Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis, *American Journal of Clinical Nutrition*, 79: 362–371.
- International Osteoporosis Foundation (2009):** Calcium and Vitamin D Anti-osteoporotic drugs and calcium/vitamin D supplementation, found at {<http://www.iofbonehealth.org/health-professionals/about-osteoporosis/treatment/calcium-vitamin-d.html>}, accessed: 18 September 2010
- Jackson RD, LaCroix AZ, Gass M, et al (2006):** Calcium plus vitamin D supplementation and the risk of fractures., *N Engl J Med*;354:669-683.
- Jazrawi L., Bai B., Simon J., Kummer F., Birdzell L., Koval K. (2000):** A biomechanical comparison of Schuhli nuts or cement augmented screws for plating of humeral fractures, *Clin Orthop Relat Res.* ;377:235-240
- Juppner H (2006):** In Parathyroid Hormone and Parathyroid Hormone-Related Peptide in the Regulation of Calcium Homeostasis and Bone Development. Degroot, L.J. & J.L. Jameson (eds): *Endocrinology*, 5th ed. Philadelphia, Elsevier; p. 1377.
- Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR., (1999):** Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group., *Arch Intern Med.*;59:1215–1220.
- Kanis JA (1994):** Calcium metabolism and disorder of bone. In : *Scientific Foundation of biochemistry in Clinical Practice*, 2<sup>nd</sup> ed., D.L. Williams and V. Marks (eds.) , Butterworthheinemann, Oxford, p. 515.
- Kanis JA, Johansson H, Johnell O, et al (2005):** Alcohol intake as a risk factor for fracture, *Osteoporos Int* ;16:737-742.
- Kannus P, Palvanen M, Niemi S, et al. (2000):** Epidemiology of Osteoporotic Pelvic Fractures in Elderly People in Finland: Sharp Increase in 1970–1997

- and alarming projections for the new millennium., *Osteoporosis Int*; 11: 443–8
- Kassem M, Harris SA, Spelsberg TC and Riggs BL (1996):** Estrogen inhibits interleukin-6 production and gene expression in human osteoblastic cell line with high estrogen receptors., *J.Bone. Miner. Res.*; 11 : 193-199.
- Khan AN, MacDonald S and Guglielmi G (2008):** Osteoporosis, Involutional. , found at: <http://emedicine.medscape.com/article/393602-overview> , accessed: 18 August 2010
- Kool B, Ameratunga S, Robinson E, Crengle S, Jackson R. (2008):**The contribution of alcohol to falls at home among working-aged adults, *Alcohol* ;42:383-388.
- Krane SM and Holick MF (1997):** Metabolic bone disease, In : *Harrison's Principles of Internal Medicine*, 11<sup>th</sup> ed., E .Brauwald , K.J. Isselbacher, R.G. Petersdorf, J.B. Martin and A.S. Fauci (eds.), McGraw Hill Book Co., New York: P 1892.
- Kumei Y, Morita S, Nakamura H, et al. (2004):** Osteoblast responsiveness to 1-  
\* alpha-dihydroxyvitamin D3 during spaceflight. *Ann N Y Acad Sci.*;1030:121–124.
- Kvetny J (2005):** Subclinical hyperthyroidism in patients with nodular goiter represents a hypermetabolic state., *Exp Clin Endocrinol Diabetes*; 113: 122-126.
- Lane N(2006):** Epidemiology, etiology, and diagnosis of osteoporosis, *American Journal of Obstetrics and Gynecology* ;194, S3–11
- Lau E, Sambrook P, Seeman E, et al. (2006):** Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia., *APLAR Journal of Rheumatology*; 9: 24–36.
- Lepore S (2002):** An Inflatable Self-Locking System for Long Bone Fractures., *Osteo. Trauma Care* ; 10: S32-S35
- Licata AA (2005):** Discovery, clinical development, and therapeutic uses of
-

bisphosphonates. *Annals of Pharmacotherapy*; 39: 668–677.

**Lindsay R, Gallagher JC, Kleerekoper M and Pickar JH (2002):** Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women, *JAMA*; 287: 2667-2668

**Lippuner K, Golder M, Greiner R. (2004):** Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland., *Osteoporos Int.*, 16 (2): S8–S17.

**Manolagas SC and Jilka RL (1995):** Bone marrow, cytokines , and bone remodeling., *N. Eng. J. Med*; 332 : 303-311.

**Marcucci G and Brandi M (2009):**Vertebroplasty and balloon kyphoplasty in osteoporosis: friends or foes?, *Clinical Cases in Mineral and Bone Metabolism* ; 6(3): 203-209

**Marcus R (1998):** Editorial : New Perspectives on the skeletal role of estrogen. *J. Clin. Endocrinol. Metab.* ; 83 : 2236-2238.

**Marques-Neto F., Reid D., Hosking D., Kendler D., Brandi M., Wark J., Weryha G., Verbruggen N., Hustad C. and Mahlis E. (2006):** Greater gains in bmd with alendronate than risedronate after 24 months: results of fosamax ® actonel® comparison trials (facts) – international , *Journal of Clinical Rheumatology* ;12(4) : S28-s29

**Martens G and Shaw H.(2008):** Maximizing Effectiveness of Bisphosphonate Therapy for Osteoporosis, *Southern Medical Journal* ; 101(8) :828-829

**McEvoy G, Snow E, Kester L, et al. (2006):** American Hospital Formulary Service (AHFS): Drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists: p. 3047.

**Mckinlay SM, Brambilla DJ and Posner JG(1992):** The normal menopause transition. *Maturitas* ;4 : 103- 115.

**Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA**

- (2004):** Seven years of treatment with risedronate in women with postmenopausal osteoporosis, *Calcif Tissue Int*;75:462-468.
- Miller PD, Chines AA, Christiansen C, et al. (2008):** Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. *J Bone Miner Res*;23:525-535.
- Moore C, Murphy MM, Keast DR, et al. (2004).** Vitamin D intake in the United States., *Journal of the American Dietetic Association*; 104: 980–983.
- Mori S(2003):** Fracture healing with anti-resorptive agents *J Musculoskel Neuron Interact* 2003; 3(4):314-316
- Moroni A. et al., (2003):** Use of hydroxyapatite (HA)-coated dynamic hip screw (DHS)-system in patient osteoporotic, *Clin. Orthop.* ; 408:262-267
- Mourad LA, Hoare K and Donahoe KM (1994):** Structure and Function of the musculoskeletal system. In : *Pathophysiology : The Biologic Basis for Disease in Adults and Children* , 2<sup>nd</sup> (ed) , K.L. Mecanceand and S. E. Huether (eds.) , Mosby, P. 1404.
- Murry RK and Keeley FW (2000):** The Extracellular Matrix . In : *Harper’s Biochemistry* . 25<sup>th</sup> ed. R.K. Murray , D.K. Granner, P.A. Mayes and V.W. Rodwell. (eds.), Librairie du Liban, P.708.
- National Institutes of Health(2009):** Dietary Supplement Fact Sheet: Vitamin D, found at: <http://ods.od.nih.gov/factsheets/vitamind.asp#en93> , accessed: 19 September 2010
- National Osteoporosis Foundation (2003):** Physician’s guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation: p. 1
- National Osteoporosis Foundation (2008):** Vitamin D and Bone Health, found at {<http://www.nof.org/prevention/vitaminD.htm>}, accessed: 18 September 2010
- Newitt DC, Rietbergen VB and Majumdar S (2002):** Processing and analysis of

- in vivo high-resolution MR images of trabecular bone for longitudinal studies: reproducibility of structural measures and micro-finite element analysis derived mechanical properties., *Osteoporosis Int.*; 13 (4): 278-287.
- Ng KW (2009):** Future Developments in Osteoporosis Therapy, *Endocrine, Metabolic & Immune Disorders - Drug Targets* ;9: 371-384
- Nochowitz B, Siegert S and Wasik M (2009):** An Update on Osteoporosis, *American Journal of Therapeutics* 16, 437–445
- Noorda R. and Wuisman P (2002):** Mennen Plate Fixation for the Treatment of Periprosthetic Femoral Fractures A Multicenter Study of Thirty-six Fractures ,*The Journal of Bone and Joint Surgery (American)*; 84:2211-2215
- Ojo F, Al Snih S, Ray LA, MA, et al. (2007):** "History of fractures as predictor of subsequent hip and non-hip fractures among older Mexican Americans". *Journal of the National Medical Association*; 99 (4): 412-418.
- Orbay J. (2005) :** Volar Plate Fixation of Distal Radius Fractures, *Hand Clin* ;21 : 347–354
- Orbay J., (2003):** Advances in Distal Radius fixation. , *Orthopedic Technology Review*;5 (2): 30
- Pageau SC (2009):** Mini-Review: Denosumab, mAbs; 1 (3) : 210-215
- Pal B, Morris J, Muddu B(1998):** The management of osteoporosis- related fractures: A survey of orthopaedic surgeons' practice. *Clin Exper Rheumatol* 16:61–62
- Parfitt AM (1997):** Quantum concept of bone remodeling and turnover: implication for the pathogenesis of osteoporosis .*Calcif. Tissue. Int.*; 28: 1-5.
- Parker MJ, Gillespie WJ, Gillespie LD (2005):** Hip protectors for preventing hip fractures in older people. *Cochrane Database Syst Rev* ; 3:CD001255.
- Perren S. (2002):** Evolution of the internal fixation of long bone *J Bone Joint Surg [Br]* ; 84-B:1093-110.
- Petty SJ, O'Brien TJ and Wark JD (2007):** "Anti-epileptic medication and bone

- health". Osteoporosis int; 18 (2): 129–142.
- Phadnis R and Nemere I (2003):** Calcium and phosphorus metabolism. J. Cell. Biochem. 90: 287–288.
- Pinkerton J., Dalkin A. (2007):** Combination therapy for treatment of osteoporosis: A review, American Journal of Obstetrics & Gynecology ;December 2007 :565-565
- Poltratz ST, Bellido T, Mocharla H, Crabb D and Manolagas SC (1994):** 17  $\beta$  - estradiol inhibits expression of human interleukin-6 promoter receptor constructs by a receptor dependant mechanism. J. Clin. Invest., 93: 944-950.
- Qaseem A, Snow V, Hopkins R Jr, Forciea MA and Owens DK (2008):** Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians ,Annals of Internal Medicine ;149 (6): 404-415
- Raisz LG (2005):** Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115: 3318-3325.
- Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL. (2000):**Smoking and bone metabolism in elderly women, Bone ;27:429-436.
- Razzaque (2005):** Calcium and phosphorus metabolism., Nephrol. Dial. Transplant.; 20: 2032–2022.
- Ring D, Jupiter J (2005):** Treatment of osteoporotic distal radius fractures. ,Osteoporosis Int; 16 (2):S80-84
- Rizzoli R(2007) :** a tribute to Herbert Fleisch , osteoporosis Int., 18:1151
- Rosen CJ (2003):** Restoring aging bones. Sci Am; 288 (3): 70-77.
- Rosier RN (2001):** Expanding the Role of the Orthopedic Surgeon in the Treatment of Osteoporosis, clinical orthopaedics and related research; 385L: 57–67
- Schapira D., and Schapira C. (1992):** Osteoporosis: the evolution of a scientific term. Osteoporos. Int. 2:164–167.
-

- Schatzker J (1998):** Fractures of the distal femur revisited., Clin Orthop 1998;347:43-56.
- Schiller AI (1999):** Bones and Joints. In: pathology. 2nd ed. E.Rubin and J.L. farber (eds.). J.B. Lippincott Co. Philadelphia: P 1274.
- Schneider DL, Bettencourt R and Barrett-Connor E. (2006):** Clinical utility of spine bone density in elderly women. J Clin Densitom.; 9 (3): 255-260.
- Sebba A (2008):** Osteoporosis: how long should we treat?, Current Opinion in Endocrinology, Diabetes & Obesity; 15:502–507
- Seeman E (2003):** Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporosis Int.; 14 (1 3): S2-8.
- Serota AC, Lane JM, Slipman CW, et al. (2006):** Osteoporosis (Secondary), found at: <http://emedicine.medscape.com/article/311449-overview>, accessed: 9 January 2011
- Siminoski K, Warshawski RS, Jen H, Lee K (2003):** Accuracy of physical examination using the rib-pelvis distance for detection of lumbar vertebral fractures. Am J Med.; 115:233-236.
- Simon LS (2005):** Osteoporosis. Clinics in Geriatric Medicine; 21: 603–629.
- Stevenson M, Lloyd M, Nigris E, Brewer N, Davis S and Oakley J(2005) :** A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and Teriparatide for the prevention and treatment of postmenopausal osteoporosis , Health Technology Assessment.;9 (22):p.129
- Stucke SA, Lombardi BM, Gueldner SH and Grabo TN (2008):** The Pathogenesis of Osteoporosis In Gueldner SH, Grabo TN, Newman ED (eds), Osteoporosis: Clinical guidelines for prevention, diagnosis and management(5th ed.), Springer Publishing Company:p19–29
- Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Johnes ST, Boyde A and Suda T (1998):** Osteoclast like cell formation and its regulation

- by osteoporotic hormones in mouse bone marrow cultures. *Endocrinology*; 122 : 1373- 1382.
- Torgerson, DJ; Avenell, A and Russell, IT(1994):** Factors associated with onset of menopause in women aged 45- 49. *Maturitas* 19: 83- 92.
- Treatments for osteoporosis website (2010):** history of osteoporosis , available at: <http://treatmentsforosteoporosis.net/history-of-osteoporosis/> , accessed: 14 October 2010
- Tucker KL (2003):** Dietary intake and bone status with aging. *Current Pharmaceutical Design*; 9: 2687–2704.
- Vasikaran SD, Glendenning P and Morris HA (2006):** The Role of Biochemical Markers of Bone Turnover in Osteoporosis Management in Clinical Practice. *Clin Biochem Rev*; 27 (3): 119–121.
- Walcher F. et al., (2000):** Retrograde Nailing of Distal Femoral Fracture - Clear and Potential Indications., *Eur. J. Trauma* ; 26:155–68
- Walker J and Saha S (2003):** The Use of Bone Cement in the Treatment of Osteoporotic Fractures, In *Orthopaedic issues in osteoporosis*, An Y(eds.),CRC Press, Florida;17:344
- Watts B, Worley K, Solis A, Doyle J, and Sheer R (2004):** Comparison of Risedronate to Alendronate and Calcitonin for Early Reduction of Nonvertebral Fracture Risk: Results From a Managed Care Administrative Claims Database, *Journal of Managed Care Pharmacy JMCP* ;10 (2):150
- Weaver C (2006):** Calcium. In B. A. Bowman & P. M. Russell (Eds.), *Present knowledge in nutrition* (9<sup>th</sup> ed.). Washington, DC: International Life Sciences Institute; pp. 273–282.
- Weismiller DG (2002):** The Perimenopause and Menopause Experience. *Clinics in Family Practice* ; 4(1):1-12.
- Weitzmann MN and Pacifici R, (2005):** The role of T lymphocytes in bone metabolism. *Immunolo Rev*; 208: 154- 168.



- WHO Scientific Group (2003):** The Burden of Musculoskeletal Conditions at the Start of the Millennium. Technical report series no 919. Geneva, WHO.
- WHO scientific group, (2004):** who scientific group on the assessment of osteoporosis at primary health care level, available: <http://www.who.int/chp/topics/Osteoporosis.pdf> , accessed: 11 August 2010
- Wong PK, Christie JJ and Wark JD (2007):** "The effects of smoking on bone health". Clin. Sci; 113 (5): 233–241.
- World Health Organization (2010):** Metrics: Disability-Adjusted Life Year (DALY),available: [http://www.who.int/healthinfo/global\\_burden\\_disease/metrics\\_daly/en/index.html](http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/index.html), accessed: 11 August 2010
- Wrotny C (2005):** Osteoporosis: What Women Want to Know, Medsurg Nursing;14 (6):404-415